Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
60
Views
15
CrossRef citations to date
0
Altmetric
Original Research

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

James C Yao1 GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TXCorrespondence[email protected]
,
Jennifer A Chan2 Gastrointestinal Cancer Center, Dana–Farber Cancer Institute, Boston, MA
,
Alain C Mita3 Experimental Therapeutics, Cedars-Sinai Medical Center, Los Angeles, CA
,
Madan G Kundu4 Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ
,
Karina Hermosillo Reséndiz4 Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ
,
Ke Hu4 Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ
,
Shoba Ravichandran4 Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ
,
Jonathan R Strosberg5 Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
&
Edward M Wolin6 Oncology, Montefiore Einstein Center for Cancer Care, Bronx, NY, USA
 show all
Pages 3177-3186 | Published online: 27 Jun 2017

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Anna Angelousi, Anna Koumarianou, Eleftherios Chatzellis & Gregory Kaltsas. (2023) Resistance of neuroendocrine tumours to somatostatin analogs. Expert Review of Endocrinology & Metabolism 18:1, pages 33-52.
Read now
Gherardo Mazziotti, Alessandra Mosca, Stefano Frara, Giovanni Vitale & Andrea Giustina. (2017) Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opinion on Pharmacotherapy 18:16, pages 1679-1689.
Read now

Articles from other publishers (13)

Kristen McClellan, Emerson Y. Chen, Adel Kardosh, Charles D. Lopez, Jaydira Del Rivero, Nadine Mallak, Flavio G. Rocha, Yilun Koethe, Rodney Pommier, Erik Mittra & Guillaume J. Pegna. (2022) Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. Cancers 14:19, pages 4769.
Crossref
E. Vitali, S. Piccini, G. Trivellin, V. Smiroldo, E. Lavezzi, A. Zerbi, G. Pepe & A.G. Lania. (2021) The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Molecular and Cellular Endocrinology 527, pages 111226.
Crossref
Anna La Salvia, Paula Espinosa-Olarte, Maria Del Carmen Riesco-Martinez, Beatriz Anton-Pascual & Rocío Garcia-Carbonero. (2021) Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?. Cancers 13:7, pages 1701.
Crossref
Maria Luisa Brandi, Sunita K Agarwal, Nancy D Perrier, Kate E Lines, Gerlof D Valk & Rajesh V Thakker. (2021) Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocrine Reviews 42:2, pages 133-170.
Crossref
Mariana Gomes-Porras, Jersy Cárdenas-Salas & Cristina Álvarez-Escolá. (2020) Somatostatin Analogs in Clinical Practice: A Review. International Journal of Molecular Sciences 21:5, pages 1682.
Crossref
Magaly Vialon, Rachel Desailloud & Philippe Caron. (2019) La néoplasie endocrinienne multiple de type 1 : mise au point après le congrès de l’ENETS 2019. Annales d'Endocrinologie 80, pages S19-S28.
Crossref
Federico Gatto, Federica Barbieri, Marica Arvigo, Stefano Thellung, Jessica Amarù, Manuela Albertelli, Diego Ferone & Tullio Florio. (2019) Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. International Journal of Molecular Sciences 20:16, pages 3940.
Crossref
Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas & Anna Koumarianou. (2019) Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocrine Connections 8:6, pages 641-653.
Crossref
Aura D. Herrera-Martínez, Johannes Hofland, Leo J. Hofland, Tessa Brabander, Ferry A. L. M. Eskens, María A. Gálvez Moreno, Raúl M. Luque, Justo P. Castaño, Wouter W. de Herder & Richard A. Feelders. (2018) Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 79:1, pages 21-42.
Crossref
Wouter W. de Herder. (2018) When and How to Use Somatostatin Analogues. Endocrinology and Metabolism Clinics of North America 47:3, pages 549-555.
Crossref
Giovanni Vitale, Alessandra Dicitore, Concetta Sciammarella, Sergio Di Molfetta, Manila Rubino, Antongiulio Faggiano & Annamaria Colao. (2018) Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. Endocrine-Related Cancer 25:6, pages R351-R364.
Crossref
Morten Frost, Kate E. Lines & Rajesh V. Thakker. (2018) Current and emerging therapies for PNETs in patients with or without MEN1. Nature Reviews Endocrinology 14:4, pages 216-227.
Crossref
Tetsuhide Ito, Lingaku Lee & Robert T. Jensen. (2018) Carcinoid-syndrome. Current Opinion in Endocrinology & Diabetes and Obesity 25:1, pages 22-35.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.